Combining low-dose or metronomic chemotherapy with anticancer vaccines

Therapeutic vaccination is regarded as a promising strategy against multiple hematological malignancies including lymphoma. However, this approach alone possesses limited potential for the treatment of established tumors. As several anticancer regimens relies on the combination of multiple drugs, it is reasonable to predict that also cancer vaccination will be most effective in the context of multimodal approaches. In particular, low-dose or metronomic chemotherapy could be coupled to anticancer vaccines to improve the efficacy of this immunotherapeutic interventions. This review summarizes recent findings in support of the use of anticancer vaccines combined with low-dose or metronomic chemotherapy for the treatment and management of lymphoid malignancies.

[1]  M. Coleman,et al.  Metronomic therapy for refractory/relapsed lymphoma: the PEP-C low-dose oral combination chemotherapy regimen , 2012, Hematology.

[2]  R. Kalluri,et al.  Thrombospondin-1 Associated with Tumor Microenvironment Contributes to Low-Dose Cyclophosphamide-Mediated Endothelial Cell Apoptosis and Tumor Growth Suppression , 2004, Cancer Research.

[3]  R. Kerbel,et al.  Maximum tolerable dose and low-dose metronomic chemotherapy have opposite effects on the mobilization and viability of circulating endothelial progenitor cells. , 2003, Cancer research.

[4]  R. Kerbel,et al.  Thrombospondin 1, a mediator of the antiangiogenic effects of low-dose metronomic chemotherapy , 2003, Proceedings of the National Academy of Sciences of the United States of America.

[5]  N. Siafakas,et al.  Angiogenic molecules in Hodgkin's disease: results from sequential serum analysis. , 2006, International journal of immunopathology and pharmacology.

[6]  S. Poppema,et al.  Absence of HLA class I expression by Reed-Sternberg cells. , 1994, The American journal of pathology.

[7]  Y. Chu,et al.  CD4+Foxp3+ Regulatory T‐cell Impairment by Paclitaxel is Independent of Toll‐like Receptor 4 , 2011, Scandinavian journal of immunology.

[8]  S. Mattarollo,et al.  Chemotherapy pretreatment sensitizes solid tumor‐derived cell lines to Vα24+ NKT cell‐mediated cytotoxicity , 2006, International journal of cancer.

[9]  R. Willemze,et al.  Expression of Fas and Fas‐ligand in primary cutaneous T‐cell lymphoma (CTCL): association between lack of Fas expression and aggressive types of CTCL , 2000, The British journal of dermatology.

[10]  H. Bear,et al.  Gemcitabine directly inhibits myeloid derived suppressor cells in BALB/c mice bearing 4T1 mammary carcinoma and augments expansion of T cells from tumor-bearing mice. , 2009, International immunopharmacology.

[11]  S. Sakaguchi.  Regulatory T cells , 2006, Springer Seminars in Immunopathology.

[12]  Yu Zeng,et al.  Low concentrations of doxorubicin sensitizes human solid cancer cells to tumor necrosis factor‐related apoptosis‐inducing ligand (TRAIL)‐receptor (R) 2‐mediated apoptosis by inducing TRAIL‐R2 expression , 2007, Cancer science.

[13]  I. Tannock,et al.  Repopulation of cancer cells during therapy: an important cause of treatment failure , 2005, Nature Reviews Cancer.

[14]  Srinivas Nagaraj,et al.  Myeloid-derived suppressor cells as regulators of the immune system , 2009, Nature Reviews Immunology.

[15]  L. Bracci,et al.  Cyclophosphamide synergizes with type I interferons through systemic dendritic cell reactivation and induction of immunogenic tumor apoptosis. , 2011, Cancer research.

[16]  K. Mross,et al.  Metronomic anti-cancer therapy - an ongoing treatment option for advanced cancer patients , 2012 .

[17]  P. Zabel,et al.  Myeloid‐derived suppressor cells in the peripheral blood of cancer patients contain a subset of immature neutrophils with impaired migratory properties , 2011, Journal of leukocyte biology.

[18]  S. Altiok,et al.  Chemotherapy enhances tumor cell susceptibility to CTL-mediated killing during cancer immunotherapy in mice. , 2010, The Journal of clinical investigation.

[19]  R. Sun,et al.  Opposing effect of IFNgamma and IFNalpha on expression of NKG2 receptors: negative regulation of IFNgamma on NK cells. , 2005, International immunopharmacology.

[20]  D. Ribatti,et al.  The role of angiogenesis in human non-Hodgkin lymphomas. , 2013, Neoplasia.

[21]  Michael C. Schmid,et al.  Myeloid Cells in the Tumor Microenvironment: Modulation of Tumor Angiogenesis and Tumor Inflammation , 2010, Journal of oncology.

[22]  Wenru Song,et al.  Therapeutic vaccination against murine lymphoma by intratumoral injection of naive dendritic cells. , 2005, Cancer research.

[23]  H. Rammensee,et al.  Cutting Edge: Down-Regulation of MICA on Human Tumors by Proteolytic Shedding , 2002, The Journal of Immunology.

[24]  S. Lowe,et al.  NKT cell adjuvant-based tumor vaccine for treatment of myc oncogene-driven mouse B-cell lymphoma. , 2012, Blood.

[25]  V. Rozados,et al.  Metronomic therapy with cyclophosphamide induces rat lymphoma and sarcoma regression, and is devoid of toxicity. , 2004, Annals of oncology : official journal of the European Society for Medical Oncology.

[26]  J. Blay,et al.  CD4+CD25+ regulatory T cells inhibit natural killer cell functions in a transforming growth factor–β–dependent manner , 2005, The Journal of experimental medicine.

[27]  F. Chen,et al.  Subtoxic concentration of doxorubicin enhances TRAIL-induced apoptosis in human prostate cancer cell line LNCaP , 2005, Prostate Cancer and Prostatic Diseases.

[28]  J. Coligan,et al.  Complex regulation of human NKG2D-DAP10 cell surface expression: opposing roles of the γc cytokines and TGF-β1. , 2011, Blood.

[29]  S. Akira,et al.  Lymphoma Immunotherapy with CpG Oligodeoxynucleotides Requires TLR9 Either in the Host or in the Tumor Itself1 , 2007, The Journal of Immunology.

[30]  Jun Liang,et al.  Low‐dose metronomic chemotherapy with cisplatin: can it suppress angiogenesis in H22 hepatocarcinoma cells? , 2010, International journal of experimental pathology.

[31]  L. Zitvogel,et al.  Tumor cell death and ATP release prime dendritic cells and efficient anticancer immunity. , 2010, Cancer research.

[32]  P. De Baetselier,et al.  Identification of discrete tumor-induced myeloid-derived suppressor cell subpopulations with distinct T cell-suppressive activity. , 2008, Blood.

[33]  Z. Tian,et al.  Interleukin-15 improves cytotoxicity of natural killer cells via up-regulating NKG2D and cytotoxic effector molecule expression as well as STAT1 and ERK1/2 phosphorylation. , 2008, Cytokine.

[34]  M. Bernard,et al.  Major histocompatibility complex abnormalities in non‐Hodgkin lymphomas , 2002, British journal of haematology.

[35]  N. Harashima,et al.  Metronomic chemotherapy with low-dose cyclophosphamide plus gemcitabine can induce anti-tumor T cell immunity in vivo , 2013, Cancer Immunology, Immunotherapy.

[36]  N. Schmitz,et al.  Frontline therapy with rituximab added to the combination of cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) significantly improves the outcome for patients with advanced-stage follicular lymphoma compared with therapy with CHOP alone: results of a prospective randomized study of t , 2005, Blood.

[37]  J. Vincent,et al.  5-Fluorouracil selectively kills tumor-associated myeloid-derived suppressor cells resulting in enhanced T cell-dependent antitumor immunity. , 2010, Cancer research.

[38]  A. Anichini,et al.  Vaccination with autologous tumor-loaded dendritic cells induces clinical and immunologic responses in indolent B-cell lymphoma patients with relapsed and measurable disease: a pilot study. , 2009, Blood.

[39]  P. Cano,et al.  Phase II Clinical Trial Results Involving Treatment with Low-Dose Daily Oral Cyclophosphamide, Weekly Vinblastine, and Rofecoxib in Patients with Advanced Solid Tumors , 2006, Clinical Cancer Research.

[40]  I. Borrello,et al.  Myeloid-derived suppressor cells promote cross-tolerance in B-cell lymphoma by expanding regulatory T cells. , 2008, Cancer research.

[41]  A. Dietz,et al.  Immunosuppressive CD14+HLA-DR(low)/- monocytes in B-cell non-Hodgkin lymphoma. , 2011, Blood.

[42]  R. Foà,et al.  ATM-ATR-dependent up-regulation of DNAM-1 and NKG2D ligands on multiple myeloma cells by therapeutic agents results in enhanced NK-cell susceptibility and is associated with a senescent phenotype. , 2009, Blood.

[43]  B. Chauffert,et al.  Metronomic cyclophosphamide regimen selectively depletes CD4+CD25+ regulatory T cells and restores T and NK effector functions in end stage cancer patients , 2007, Cancer Immunology, Immunotherapy.

[44]  K. Ohkusu-Tsukada,et al.  Targeted inhibition of IL‐10‐secreting CD25− Treg via p38 MAPK suppression in cancer immunotherapy , 2010, European journal of immunology.

[45]  A. Dalgleish,et al.  Pre-treatment with chemotherapy can enhance the antigenicity and immunogenicity of tumours by promoting adaptive immune responses , 2009, British Journal of Cancer.

[46]  G. Konjević,et al.  The difference in NK‐cell activity between patients with non‐Hodgkin's lymphomas and Hodgkin's disease , 1999, British journal of haematology.

[47]  E. Santiesteban,et al.  Metronomic Cyclophosphamide and Methotrexate Chemotherapy Combined with 1E10 Anti-Idiotype Vaccine in Metastatic Breast Cancer , 2011, International journal of breast cancer.

[48]  P. van Endert,et al.  Anticancer chemotherapy-induced intratumoral recruitment and differentiation of antigen-presenting cells. , 2013, Immunity.

[49]  M. Gerken,et al.  Treatment of B cell lymphoma with chemotherapy plus rituximab: a survival benefit can be demonstrated in the routine data of a regional cancer registry , 2012, Annals of Hematology.

[50]  A Steinle,et al.  NK cells and cancer immunosurveillance , 2008, Oncogene.

[51]  Steven Piantadosi,et al.  Timed sequential treatment with cyclophosphamide, doxorubicin, and an allogeneic granulocyte-macrophage colony-stimulating factor-secreting breast tumor vaccine: a chemotherapy dose-ranging factorial study of safety and immune activation. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[52]  J. Folkman,et al.  Antiangiogenic scheduling of chemotherapy improves efficacy against experimental drug-resistant cancer. , 2000, Cancer research.

[53]  R. Marcus,et al.  Follicular lymphoma: time for a re-think? , 2005, Blood reviews.

[54]  Z. Tian,et al.  Interleukin-12 improves cytotoxicity of natural killer cells via upregulated expression of NKG2D. , 2008, Human immunology.

[55]  M. Smyth,et al.  Cyclophosphamide Chemotherapy Sensitizes Tumor Cells to TRAIL-Dependent CD8 T Cell-Mediated Immune Attack Resulting in Suppression of Tumor Growth , 2009, PloS one.

[56]  V. Umansky,et al.  T Cells Favoring Tumor Growth CCR 5-Dependent Recruitment of Regulatory Myeloid-Derived Suppressor Cells Mediate Tumor-Infiltrating Monocytic , 2012 .

[57]  C. Yee,et al.  Tumour-derived soluble MIC ligands impair expression of NKG2D and T-cell activation , 2002, Nature.

[58]  M. Manns,et al.  Myeloid derived suppressor cells in human diseases. , 2011, International immunopharmacology.

[59]  T. Nomura,et al.  CTLA-4 Control over Foxp3+ Regulatory T Cell Function , 2008, Science.

[60]  N. Harashima,et al.  Immunogenic chemotherapy with cyclophosphamide and doxorubicin against established murine carcinoma , 2010, Cancer Immunology, Immunotherapy.

[61]  G. Gasparini,et al.  Metronomic scheduling: the future of chemotherapy? , 2001, The Lancet. Oncology.

[62]  T. Di Pucchio,et al.  Cyclophosphamide induces type I interferon and augments the number of CD44(hi) T lymphocytes in mice: implications for strategies of chemoimmunotherapy of cancer. , 2000, Blood.

[63]  Drew A. Torigian,et al.  Autologous lysate-pulsed dendritic cell vaccination followed by adoptive transfer of vaccine-primed ex vivo co-stimulated T cells in recurrent ovarian cancer , 2013, Oncoimmunology.

[64]  F. Végran,et al.  Dacarbazine-mediated upregulation of NKG2D ligands on tumor cells activates NK and CD8 T cells and restrains melanoma growth. , 2013, The Journal of investigative dermatology.

[65]  M. Gobbi,et al.  High ERp5/ADAM10 expression in lymph node microenvironment and impaired NKG2D ligands recognition in Hodgkin lymphomas. , 2012, Blood.

[66]  Li-li Feng,et al.  Cyclic adenosine monophosphate involvement in low-dose cyclophosphamide-reversed immune evasion in a mouse lymphoma model , 2012, Cellular and Molecular Immunology.

[67]  R. Barker,et al.  Immunosuppressive regulatory T cells are abundant in the reactive lymphocytes of Hodgkin lymphoma. , 2004, Blood.

[68]  R. Barker,et al.  Local and systemic induction of CD4+CD25+ regulatory T-cell population by non-Hodgkin lymphoma. , 2008, Blood.

[69]  T. Lister,et al.  Low-dose continuous chemotherapy (LBCMVD-56) for refractory and relapsing lymphoma. , 2000, Annals of oncology : official journal of the European Society for Medical Oncology.

[70]  D. Berry,et al.  Vaccination with patient-specific tumor-derived antigen in first remission improves disease-free survival in follicular lymphoma. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[71]  F. Ghiringhelli,et al.  Cancer chemotherapy: not only a direct cytotoxic effect, but also an adjuvant for antitumor immunity , 2008, Cancer Immunology, Immunotherapy.

[72]  Yulia Nefedova,et al.  Epigenetic silencing of retinoblastoma gene regulates pathologic differentiation of myeloid cells in cancer , 2012, Nature Immunology.

[73]  H. Perroud,et al.  Therapeutic efficacy of metronomic chemotherapy with cyclophosphamide and doxorubicin on murine mammary adenocarcinomas. , 2013, Annals of oncology : official journal of the European Society for Medical Oncology.

[74]  L. Bracci,et al.  Cyclophosphamide Enhances the Antitumor Efficacy of Adoptively Transferred Immune Cells through the Induction of Cytokine Expression, B-Cell and T-Cell Homeostatic Proliferation, and Specific Tumor Infiltration , 2007, Clinical Cancer Research.

[75]  A. Rothe,et al.  Rescue of Impaired NK Cell Activity in Hodgkin Lymphoma With Bispecific Antibodies In Vitro and in Patients , 2013, Molecular therapy : the journal of the American Society of Gene Therapy.

[76]  J. Živný,et al.  Resistance to TRAIL in mantle cell lymphoma cells is associated with the decreased expression of purine metabolism enzymes. , 2013, International journal of molecular medicine.

[77]  R. Sun,et al.  Opposing effect of IFNγ and IFNα on expression of NKG2 receptors: Negative regulation of IFNγ on NK cells , 2005 .